Nina Vadiei
Biographic Data
| ID | 7967337 |
|---|---|
| NAME | Nina Vadiei |
| GIVEN NAMES | Nina |
| FAMILY NAME | Vadiei |
| SIGNATURE | VADIEI N |
| AFFILIATIONS | Austin College |
| ORCID | 0000-0003-3984-0317 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Real-world effectiveness and safety of xanomeline and trospium for treatment-resistant schizophrenia in a state hospital system
In inpatients with TRS taking adjunct DRBAs (including anticholinergic DRBAs) XT use was commonly discontinued due to intolerability/ineffectiveness. Larger controlled trials are needed to further investigate XT's effectiveness for treating TRS and determine how adjunct anticholinergic use impacts its safety/efficacy
Antipsychotic prescribing patterns in a state psychiatric hospital with predominantly forensic admissions
High-dose antipsychotic use and APP was common in this U.S. state psychiatric hospital. Larger, multicenter studies are needed to determine how antipsychotic prescribing patterns vary between U.S. state hospitals. Testing the development and implementation of antipsychotic stewardship programs in state hospital settings is recommended to establish best practices for monitoring antipsychotic use patterns and associated health outcomes
Kratom as a potential substance use disorder harm reduction agent
Substance use disorders contribute to considerable U.S. morbidity and mortality. While effective pharmacotherapy options are available to treat opioid and alcohol use disorders, for a variety of reasons, many patients lack access to treatment or may be reluctant to seek care due to concerns such as perceived stigma or a current lack of desire to completely curtail their substance use. Furthermore, treatment options are limited for patients with s…
No prominent works on this page.
Kratom as a potential substance use disorder harm reduction agent
Substance use disorders contribute to considerable U.S. morbidity and mortality. While effective pharmacotherapy options are available to treat opioid and alcohol use disorders, for a variety of reasons, many patients lack access to treatment or may be reluctant to seek care due to concerns such as perceived stigma or a current lack of desire to completely curtail their substance use. Furthermore, treatment options are limited for patients with s…
Real-world effectiveness and safety of xanomeline and trospium for treatment-resistant schizophrenia in a state hospital system
In inpatients with TRS taking adjunct DRBAs (including anticholinergic DRBAs) XT use was commonly discontinued due to intolerability/ineffectiveness. Larger controlled trials are needed to further investigate XT's effectiveness for treating TRS and determine how adjunct anticholinergic use impacts its safety/efficacy
Antipsychotic prescribing patterns in a state psychiatric hospital with predominantly forensic admissions
High-dose antipsychotic use and APP was common in this U.S. state psychiatric hospital. Larger, multicenter studies are needed to determine how antipsychotic prescribing patterns vary between U.S. state hospitals. Testing the development and implementation of antipsychotic stewardship programs in state hospital settings is recommended to establish best practices for monitoring antipsychotic use patterns and associated health outcomes
Schizophrenia (object-oriented programming (2 works) · Schizophrenia research and treatment (2 works) · Adjunct (1 work) · Alkaloids: synthesis and pharmacology (1 work) · Anticholinergic (1 work) · Anticholinergic agents (1 work) · Antipsychotic (1 work) · Augment (1 work) · Bipolar Disorder and Treatment (1 work) · Chemical synthesis and alkaloids (1 work)